Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas’ JAK Inhibitor Smyraf Now Available for RA
July 11, 2019
- Fujifilm, Axcelead Team Up for iPS Cell-Based Drug Discovery Support
July 11, 2019
- Takeda Releases App for IBD Patients; Sharing Info with Doctors
July 11, 2019
- Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
- Sumitomo Dainippon, NCGM Launch AMR Project in Vietnam
July 10, 2019
- Riona Shows Non-Inferiority vs. Ferromia in Iron Deficiency Anemia: JT/Torii
July 10, 2019
- Long-Term Efficacy, Safety Confirmed for Hemlibra: Roche/Chugai
July 10, 2019
- Large-Scale Study Unveils 14.7% of Ovarian Cancer Patients Carry BRCA Mutations in Japan: AstraZeneca
July 10, 2019
- Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
July 9, 2019
- Eisai, Dundee Univ. Ink Oncology Drug Discovery Deal
July 9, 2019
- Vortioxetine Hits Japan PIII Target for MDD: Takeda/Lundbeck
July 9, 2019
- Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
July 8, 2019
- Keytruda Retains Top Slot in Drug Sales Ranking in June: Encise Snapshot
July 8, 2019
- Japan Ethical Drug Sales Down 3.8% in May Due to Holidays: Crecon
July 8, 2019
- CureApp’s Smoking Cessation App under Review as Medical Device; Reimbursement Price Will Be Key: President
July 8, 2019
- Genomic Profiling Tests Need More of Private Insurer Involvement: Prof.
July 5, 2019
- Allogeneic Cell Therapies Well Suited to Pharma's Biz Model, Education of Data Scientists Important: Astellas Chairman
July 4, 2019
- Claw-Back Clause Thwarted, but Majority of Takeda Shareholders Voted in Favor
July 4, 2019
- Avastin Most Prescribed Drug at Acute Hospitals in 2018
July 3, 2019
- Sumitomo Dainippon’s Napabucasin Flops in Pancreatic Cancer Trial
July 3, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…